Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients Academic Article uri icon

Overview

MeSH Major

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Maximum Tolerated Dose
  • Piperazines
  • Pyrimidines

abstract

  • Drug exposure (area under the concentration-time curve) is dose proportional for the dose range of 25 to 1,000 mg, and there is a 1.5- to three-fold drug accumulation at steady-state after once-daily dosing. Analysis of the relationship between PD (WBC reduction) and PK parameters at steady-state indicates that a dose of 400 mg or greater is required for maximal PD effect.

publication date

  • December 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2004.03.050

PubMed ID

  • 14990650

Additional Document Info

start page

  • 935

end page

  • 42

volume

  • 22

number

  • 5